PetMed Express (PETS) Projected to Post Quarterly Earnings on Tuesday

PetMed Express (NASDAQ:PETS - Get Free Report) will likely be posting its Q4 2025 quarterly earnings results after the market closes on Tuesday, June 10th. Analysts expect PetMed Express to post earnings of ($0.06) per share and revenue of $54.00 million for the quarter.

PetMed Express Stock Performance

Shares of NASDAQ:PETS traded down $0.01 during midday trading on Wednesday, reaching $3.94. The company's stock had a trading volume of 78,596 shares, compared to its average volume of 269,025. The firm has a 50 day moving average price of $3.55 and a two-hundred day moving average price of $4.34. PetMed Express has a fifty-two week low of $2.90 and a fifty-two week high of $6.85. The firm has a market capitalization of $81.38 million, a price-to-earnings ratio of 394.39 and a beta of 0.76.

Insider Buying and Selling

In related news, CEO Sandra Yvette Campos sold 60,463 shares of the company's stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $3.31, for a total transaction of $200,132.53. Following the completion of the sale, the chief executive officer now owns 578,524 shares in the company, valued at approximately $1,914,914.44. This represents a 9.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Silvercape Investments Ltd purchased 7,401 shares of the stock in a transaction that occurred on Tuesday, May 20th. The stock was bought at an average cost of $3.95 per share, with a total value of $29,233.95. Following the completion of the transaction, the insider now directly owns 2,307,719 shares in the company, valued at $9,115,490.05. The trade was a 0.32% increase in their position. The disclosure for this purchase can be found here. 1.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its position in PetMed Express stock. Goldman Sachs Group Inc. lifted its holdings in PetMed Express, Inc. (NASDAQ:PETS - Free Report) by 59.3% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 33,209 shares of the company's stock after buying an additional 12,360 shares during the period. Goldman Sachs Group Inc. owned approximately 0.16% of PetMed Express worth $139,000 at the end of the most recent reporting period. 73.33% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on PETS shares. Wall Street Zen lowered shares of PetMed Express from a "buy" rating to a "hold" rating in a research note on Wednesday, May 7th. Morgan Stanley decreased their price target on shares of PetMed Express from $3.50 to $3.20 and set an "underweight" rating for the company in a research note on Thursday, April 17th.

About PetMed Express

PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.